Introduction
Prostate cancer initially regresses in response to antiandrogenic hormonal therapy or androgen deprivation. However, virtually all patients relapse with the emergence of androgen-independent tumor cells. The molecular basis accounting for androgen-independent cancer progression is not completely understood. In most androgen-independent prostate cancers, the androgen receptor (AR) and the androgen regulated gene prostate-speci®c antigen (PSA) are expressed, indicating that the AR and the downstream pathways are active in these cells despite elimination of androgen. One mechanism that has been proposed for AR activity in androgen-independent cells, is mutation in the ligand binding domain (Tilley et al., 1996) or ampli®cation of the AR gene (Visakorpi et al., 1995) which would result in the ability of these cells to sustain growth at castrated levels of androgen. An alternative mechanism is ligandindependent activation of the AR. Members of nonsteroidal signal transduction pathways such as insulinlike growth factor 1 (IGF1), epidermal growth factor (EGF; Culig et al., 1994) , HER2/neu and mitogen activated protein kinase kinase (MEKK1; Abreu-Martin et al., 1999) have been shown to activate the AR in the absence of androgen. However, additional genetic aberrations conferring a growth advantage independent of the AR pathway may also contribute to the growth of androgen-independent prostate cancers. Hormonal-independent cancer progression is associated with elevated autocrine production of multiple growth factors that may replace androgen as the primary regulator of growth (reviewed in Russell et al., 1998) .
This report identi®es a new androgen regulated gene expressed almost exclusively in the prostate that is identical to the recently described TMEFF2 gene (also known as tomoregulin, TPEF and HPP1), which was shown to be expressed in brain (Uchida et al., 1999; Horie et al., 2000) . TMEFF2 encodes a transmembrane protein containing an altered EGF-like motif and two follistatin domains that can possibly serve as growth factor binding motifs (Patthy and Nikolics, 1993; Kupprion et al., 1998; Patel, 1998) . We show that TMEFF2 is expressed prominently in normal human prostate as well as androgen-dependent prostate cancer cells but is down-regulated in androgen-independent human prostate cancers. Furthermore, forced expression of TMEFF2 in DU145 and PC3 androgenindependent prostate cancer cell lines inhibit their growth in liquid culture. Taken together, our results suggest that TMEFF2 may play a role as an androgenregulated protein that can suppress growth of human prostate cells and whose down-regulation is associated with progression to androgen-independent growth.
Results

TMEFF2 is highly expressed almost exclusively in the prostate
We identi®ed the TMEFF2 gene by subtractive hybridization, and Northern blot analysis showed that it was highly expressed in the androgen-dependent prostate cancer cell line LNCaP (2 kb major band; 3.2 kb minor band) and was undetectable in the androgen-independent prostate cancer cell lines PC3 and DU145 (Figure 1a) . Moreover, this gene was not detected in cell lines from several other tissues (e.g. lung, liver, breast, pancreas, bone and hematopoietic cells, Figure 1a ). Sequence analysis revealed that this cDNA is identical to the TMEFF2 gene (data not shown). Northern blot studies of human tissues found that TMEFF2 is highly expressed only in normal prostate and brain ( Figure 1b) . Using PCR based radiation hybrids the genomic locus of TMEFF2 was mapped to the human chromosome 2q32.1.
Quantitative real time RT ± PCR analysis of ®ve pairs of human normal and cancerous prostate primary samples showed that TMEFF2 is highly expressed in both normal and primary prostate cancer samples, similar to its expression in LNCaP cells (Figure 2 ).
Normal and primary cancer samples of human breast and lung were either negative or showed very low levels of TMEFF2 expression (data not shown). These results demonstrate that TMEFF2 is prominently expressed in normal prostate and primary prostate cancer but it is not highly expressed in other tissues. 
TMEFF2 expression is regulated by androgens
Because TMEFF2 was expressed in the androgendependent LNCaP cells but not in the androgenindependent PC3 and DU145 cells, we tested whether TMEFF2 is regulated by androgens. LNCaP cells were grown in media supplemented with charcoal-stripped (CS) FBS (to remove steroid hormones) and treated with dihydrotestosterone (DHT). Levels of TMEFF2 mRNA were low in cells grown in CS FBS, and DHT increased TMEFF2 mRNA expression in a dosedependent manner (Figure 3a) . TMEFF2 mRNA levels increased within 1 h of DHT exposure (0.01 mM) and the highest level of expression occurred at 24 h of culture with DHT ( Figure 3b) .
The eect of androgen withdrawal on TMEFF2 was measured in the androgen-dependent CWR22 human prostate cancer xenografts propagated in male mice. TMEFF2 levels markedly decreased by day 10 after castration ( Figure 3c ). PSA expression also decreased by day 4 after castration ( Figure 3c ).
TMEFF2 levels are higher in androgen-dependent human prostate cancer xenografts than in androgen-independent prostate cancer xenografts Quantitative real time RT ± PCR showed dierential expression of TMEFF2 in LAPC-9 androgen-dependent/androgen-independent (AD/AI) human prostate cancer xenografts. TMEFF2 expression was 2.1-fold higher in LAPC-9AD compared to LAPC-9AI cells (the fold-dierence was calculated as described in Materials and methods, Figure 4a ). TMEFF2 levels in LAPC-3AI human prostate cancer xenografts were even lower than those in the LAPC-9AI xenografts. Furthermore, Northern blot analysis showed that TMEFF2 was expressed at a higher level in the LAPC-4AD human prostate cancer xenografts compared to the LAPC-4AI xenografts (Figure 4b ). PSA levels were similar in both the LAPC-4AD and LAPC-4AI xenografts. Also, TMEFF2 was expressed at a high level in three additional androgen-dependent human prostate cancer xenografts: two CWR22 samples (m1, m2) and LuCaP-35 ( Figure 4c ). TMEFF2 expression was markedly down-regulated in androgenindependent CWR22R propagated in castrated male mice. Interestingly, androgen-independent CWR22R propagated in female mice had increased levels of TMEFF2 compared to the same xenografts propagated in castrated male mice, which prompted the following studies.
17b-estradiol (E2) and 1,25-dihydroxyvitamin D 3 (VD 3 ) enhanced TMEFF2 expression in LNCaP cells
Genes regulated by androgen can often be induced by ligands of other nuclear hormone receptors (Veldscholte et al., 1990; Hsieh et al., 1996) . TMEFF2 (Figure 5a, b) . The time course of TMEFF2 induction by E2 (0.01 mM) was similar to TMEFF2 induction by DHT. Also, VD 3 induced TMEFF2 in a dose-and time-dependent manner (Figure 5c, d ). TMEFF2 mRNA levels increased after 24 h of VD 3 exposure (0.1 mM) and continued to increase at 72 h of culture. IL-6 and EGF that were previously shown to activate the AR in an androgen-independent manner (Culig et al., 1994; Chen et al., 2000) did not aect TMEFF2 expression (data not shown).
Overexpression of TMEFF2 inhibits proliferation of prostate cancer cells
The structural motifs of the TMEFF2 protein suggests that it may interact with growth factors or their receptors and can thereby eect cell growth. To test this hypothesis, we generated DU145 stable cell lines (DU145/TMEFF2) that overexpressed TMEFF2 and measured their proliferative rates. We found that the growth rate of four independent DU145/TMEFF2 clones in culture was reduced by 43 ± 66% as compared with DU145/neo control cell lines (transfected with the empty vector, Figure 6a ). The eect of TMEFF2 on cell proliferation was also examined by clonogenic assays. PC3 cells were transfected with either an empty pcDNA3.1 vector or a pcDNA3.1 vector expressing TMEFF2 and these cells were cultured in the presence of G418. Expression of TMEFF2 resulted in a 34 ± 65% decrease in the number of G418-resistant colonies (Figure 6b ).
Discussion
This study identi®ed a new androgen regulated gene that is identical to the TMEFF2 gene (Uchida et al., 1999; Horie et al., 2000) . We found that TMEFF2 is highly and selectively expressed in normal brain and prostate as well as primary prostate cancer. Consistent with these results, Liang et al. (2000) also recently cloned TMEFF2 (TPEF) and showed that it was expressed predominantly in brain and prostate. Among a variety of cancer cell lines, TMEFF2 expression was only detected in the androgen-dependent cell line LNCaP. In a previous study (Uchida et al., 1999) , TMEFF2 expression was detected in poly (A)-selected RNA from the human glioblastoma cell line A172 and moderate levels were also found in the Chinese hamster ovary cell line CHO-K1 and in stomach ®broblast. By RT ± PCR TMEFF2 was also observed in the human melanoma cell line SK-Mel-28 (Liang et al., 2000) . These results show that TMEFF2 is not exclusively expressed in LNCaP and may be detected in other cell lines. By using a PCR based radiation hybrids technique, we mapped TMEFF2 to the human chromosome 2q32.1. Previously TMEFF2 was mapped by in situ hybridization to chromosome 2q33 (Liang et al., 2000) or to chromosome 2q32.3 (Young et al., 2001) . The dierences in TMEFF2 localization are probably due to the dierent methods used.
Levels of TMEFF2 in the human primary prostate cancer samples were equivalent to those found in the normal prostate. These primary cancer samples are almost assuredly androgen-dependent; in contrast, advanced metastatic prostate cancers are usually hormone-refractory. Human prostate cancer xenografts propagated in nude mice recapitulate the clinical transition from androgen-dependent to androgenindependent and facilitate the study of the pathogenesis of androgen-independent growth. We examined TMEFF2 expression following androgen withdrawal in CWR22 xenografts. Castration resulted in TMEFF2 levels that markedly decreased by day 10, suggesting that androgens regulate TMEFF2 expression. Similarly, androgen-dependent xenografts (CWR22, LuCaP-35, LAPC-4AD, LAPC-9AD) exhibited a higher level of TMEFF2 expression than androgen-independent human prostate cancer xenografts (CWR22R, Figure 4 Analysis of TMEFF2 expression in androgen-dependent and androgen-independent cells. (a) Quantitative real time RT ± PCR analysis of TMEFF2 expression in LAPC-9 androgendependent/androgen-independent (AD/AI) and LAPC-3AI xenografts. cDNAs from LAPC-9 AD/AI and LAPC-3AI cells were subjected to real time RT ± PCR as described in Figure 2 . (b) Northern blot analysis of TMEFF2 expression in LAPC-4AD/AI xenografts. (c) Northern blot analysis of TMEFF2 expression in LuCaP-35, CWR22 and CWR22R xenografts. RNA was prepared from the following samples: LAPC-4AD propagated in a male; LAPC-4AI propagated in a female; LuCaP-35 (androgendependent) propagated in a male; CWR22 (androgen-dependent) propagated in males (m1, m2); CWR22R (androgen-independent) propagated in a castrated male (mc) and CWR22R (androgenindependent) propagated in a female (f). The samples were analysed by Northern blot hybridization with a 32 P-dATP-labeled TMEFF2. The blots were reprobed with radiolabeled PSA (B) and GAPDH (B, C) probes Expression of TMEFF2 in prostate cancer cells S Gery et al
LAPC-3AI, LAPC-4AI, LAPC-9AI)
. Previously, several androgen-regulated genes including PSA were shown to be either similarly expressed or up-regulated in recurrent androgen-independent CWR22 xenografts (Gregory et al., 1998; Xu et al., 2000) . We have shown that PSA levels are similar in the LAPC-4AD/AI xenografts. TMEFF2 expression on the other hand, was lower in the androgen-independent cells than in the androgen-dependent cells. In LNCaP cells, TMEFF2 was induced in a doseand time-dependent fashion by DHT. Also, E2 and VD 3 , which were shown to activate AR regulated genes (Veldscholte et al., 1990; Hsieh et al., 1996) induced TMEFF2 expression in LNCaP cells. The AR in LNCaP cells has a point mutation enabling it to bind estrogen in addition to androgen. E2 induction of TMEFF2 may, therefore, be regulated through the AR. Alternatively, estrogen may up-regulate TMEFF2 by binding to the estrogen receptor expressed in these cells (Lau et al., 2000) . Of interest, TMEFF2 levels in the androgen-independent CWR22R xenografts propagated in castrated male mice were lower than the same xenografts propagated in female mice, suggesting that estrogen may have a role in regulating TMEFF2 expression. VD 3 metabolites induce dierentiation and/or inhibit cell proliferation of both primary cultures of human prostate cells and cancer cell lines (Campbell et al., 2000; Zhao and Feldman, 2001 ). Epidemiological studies suggest that VD 3 de®ciency may increase the risk of initiation and progression of prostate cancer (Miller, 1999) . The mechanism of VD 3 action in prostate is not completely known but could at least partly be mediated through regulation of genes, such as TMEFF2, that may eect cell growth. Analogs of VD 3 that have comparable or more potent antiproliferative eects and less side-eects, have been developed and are currently being used to treat prostate cancer (Miller, 1999; Hisatake et al., 2001; Zhao and Feldman, 2001) .
LNCaP cells grown in steroid-depleted medium for 48 h, showed decreased expression of TMEFF2. Treatment of the cells with DHT resulted in the induction of TMEFF2 within several hours. Similar reduction/induction time patterns were reported for other androgen regulated genes in culture (Xu et al., 2000 (Xu et al., , 2001 Benedit et al., 2001) . In the CWR22 xenografts, TMEFF2 expression decreased only by day 10 of androgen deprivation. In a recent study (Amler et al., 2000) , micoarray analysis was used to detect changes in gene expression following androgen-ablation in the CWR22 xenograft model. Of 120 genes whose expression was reduced at day 20 of androgen deprivation, only 33 showed decreased expression at day 8. This suggest that in vivo the eect of androgen withdrawal on gene expression may take longer than in vitro and may vary between dierent genes.
The forced expression of TMEFF2 in DU145 and PC3 cells inhibited their proliferation in liquid culture. Like many growth factors and adhesion molecules, TMEFF2 contains an EGF-like domain that can participate in protein ± protein and protein cell interactions (Appella et al., 1988) . The EGF-like domain in TMEFF2 is conserved in comparison with other members of the EGF-like family; but in TMEFF2, a conserved arginine residue is replaced by histidine. Mutation of this arginine in the human EGF, reduced the anity of EGF for its receptor to less than 0.5% of normal (Engler et al., 1990) . This suggests that TMEFF2 is a ligand and that the function of this domain is to possibly inhibit speci®c protein ± protein and/or protein ± cell interactions. A previous study showed that TMEFF2 stimulates tyrosine phosphorylation of erbB-4, suggesting that it is a ligand for the erbB-4 receptor (Uchida et al., 1999) ; however, erbB-4 is usually not expressed in prostate cancer cells (Robinson et al., 1996) . The follistatin domains of TMEFF2 are also highly conserved in comparison with those of other proteins. Follistatins are able to bind and inactivate a variety of growth factors including members of the TGF-b family, platelet-derived growth factor and vascular endothelial growth factor (Patthy and Nikolics, 1993; Kupprion et al., 1998; Patel, 1998) . The function of TMEFF2 is unknown; however, based on its functional domains, we hypothesize that it might inhibit growth factors and thereby inhibit cell proliferation. Indeed, two very recent studies showed that the TMEFF2 (TPEF, HPP1) gene is frequently hypermethylated in human tumor cells, suggesting that TMEFF2 might be a tumor suppressor gene (Liang et al., 2000; Young et al., 2001) . TMEFF2 may be inactivated not only by methylation but also by chromosome deletion because it is located on chromosome 2q where chromosomal losses have been detected in prostate cancer (Zitzelsberger et al., 2001) . Downregulation of TMEFF2 in androgen-independent prostate cancer cells may oer a growth advantage to these cells and contribute to their more aggressive phenotype compared to androgen-dependent prostate cancer cells. Of note, TMEFF2 was suggested to act as a survival factor for neurons (Horie et al., 2000) . Further studies are required to determine TMEFF2 role in brain and prostate.
In summary, we have shown that TMEFF2 is an androgen-regulated gene that is highly expressed in normal prostate cells and in androgen-dependent prostate cancers, but its expression is decreased in androgen-independent prostate cancers. We also found that forced expression of TMEFF2 in TMEFF2 nonexpressing human prostate cancer cells inhibited their growth. These data in concert with recent methylation studies (Liang et al., 2000; Young et al., 2001) , suggest that TMEFF2 may act as a tumor suppressor gene in the prostate and its inactivation is associated with androgen-independent disease progression.
Materials and methods
Prostate cancer specimens, xenografts and cell culture
Matched pairs of normal and tumor prostate specimens were obtained from UCLA, at the time of prostatectomy; the samples were micro-dissected after histological assessment. The prostate cancer xenografts LAPC-3, -4 and -9, CWR22 and LuCaP-35 have been described (Wainstein et al., 1994; Klein et al., 1997; Whang et al., 1998; Agus et al., 1999) . Androgen withdrawal was accomplished as previously described (Agus et al., 1999) . The following cell lines were used: prostate cancer (LNCaP, PC3 and DU145), breast cancer (MCF7, MDA-MB-436 and MDA-MB-231), normal breast (MCF-12A), pancreas cancer (PANC-1 and MIA PA CA-2), lung cancer (NCI-H125, NCI-H157 and NCI-H446), osteosarcoma (HOS and MG63), acute myeloid leukemia (HL-60 and U937), hepatoma (HepG2), chronic myelogenous leukemia (K-562) and T-lymphocyte (Jurkat), which were obtained from the American Type Culture Collection and grown in the recommended medium and conditions. For dihydrotestosterone (DHT), 17b-estradiol (E2) or 1,25-dihydroxyvitamin D 3 (VD 3 ) studies, 1610 6 LNCaP cells were seeded into 9-mm plates in RPMI with 10% FBS. After 24 h, cells were washed, re-suspended with RPMI with 10% charcoal-stripped serum and incubated for an additional 48 h. DHT, E2 or VD 3 were then added to the cells for various times and concentrations.
Northern blot analysis and subtractive hybridization
Total RNA was isolated from human prostate specimens, prostate cancer xenografts and cell lines using TRIzol (Life Technologies, Inc.). Subtractive hybridization was performed on the androgen-dependent prostate cell line LNCaP and the two androgen-independent prostate cell lines PC3 and DU145 with the PCR-Select TM cDNA Subtraction kit (Clontech Laboratories, Inc.). The resulting products were cloned into the pGEM-T Easy vector (Promega) and their tissue speci®city was determined using Northern analysis. For Northern analysis, 10 mg of total RNA was fractionated on 1.2% agarose denaturing gels and transferred to nylon membranes (Amersham). The human multiple tissue blots were obtained from Clontech (Laboratories, Inc.). Probes were labeled with the Strip-EZ DNA kit (Ambion) and hybridizations were performed in the ULTRAhyb buer (Ambion) according to the manufacturer's instructions.
Quantitative real time reverse transcription-PCR (RT ± PCR)
Total RNA (2 mg) from human specimens, prostate cancer xenografts or cell lines was converted into cDNA using MMLV reverse transcriptase (Life Technologies, Inc.) according to the manufacturer's instructions. The following primers and probes were used: TMEFF2 primers, 5'-GGCTGGAATTGCTCTG-GTTA-3' and 5'-AGCCTGTCGCAGGTAACACT-3'; 18S primers, 5'-AAACGGCTACCACATCCAAG-3' and 5'-CC-TCCAATGGATCCTCGTTA-3'; TMEFF2 probe, 5'-TATG-TGCCTGTGTGTGGCTCCAAT-G-3'; 18S probe, 5'-AGCA-GGCGCGCAAATTACCC-3'. Primers were synthesized by Life Technologies Inc. Probes were purchased from Applied Biosystems (Foster City, CA, USA) and were labeled with the reporter dye FAM in the 5' end and the quencher dye TAMRA in the 3' end. Ampli®cation reactions were performed with the Universal Taqman PCR mastermix (Applied Biosystems) in triplicates in an iCycler iQ TM system (Biorad, Hercules, CA, USA). The thermal cycling conditions were as follows: 2 min at 508C, 10 min at 958C, followed by 45 cycles of 958C for 15 s and 608C for 1 min. To determine fold-dierence between samples additional reactions with four serial ®vefold dilutions of LNCaP cDNA were performed to generate a standard curve, which related the threshold cycle to the log input amount of template.
Chromosomal mapping
Radiation hybrid mapping was done with the human GeneBridge 4 RH Panel (Research Genetics). The primers used were the same as the primers used for real time PCR. Results were submitted to WICGR Mapping Service by internet (www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl) which gave us the computed results.
Transfections and cell proliferation assays cDNA coding for TMEFF2 was ampli®ed from LNCaP cells with the following primes: 5'-CCGTTTGCTGCAGAGTTG-CACGAAC-3' and 5'-TCCAGCCACTGTGAAACATGCT-CCC-3' and cloned into the pcDNA3 expression vector (Invitogen). DU145 cells were transfected using the Gene-PORTER TM transfection Reagent (GTS Inc.) with 10 mg of either an empty pCDNA3.1 vector or the same vector expressing TMEFF2. Stable DU145 clones were obtained by selection in G418 (500 mg/ml). Expression of TMEFF2 was con®rmed by Northern analysis. For MTT assays, DU145/neo (transfected with the empty vector) or DU145/ TMEFF2 (transfected with the TMEFF2 expression vector) were seeded in quadruplicate in 96-well plates at 1000 cells per well. After 4 days, cell proliferation was assayed using the Cell Proliferation kit I (MTT, Boehringer Mannheim) according to the manufacturer's instructions. For colony formation assays, PC3 cells were seeded in 6-well plates and transfected using the GenePORTER TM transfection Reagent (GTS Inc.) with 2.5 mg of either the empty pCDNA3.1 vector or the same vector expressing TMEFF2. Transfected cells were grown in the presence of G418 (500 mg/ml) for 2 weeks and then stained with Giesma stain (Fisher Scienti®c).
